Argent Signs NLC Licence to Expand Antiviral Portfolio
Filed with ASX · · 6 pages · English
Earlier from Argent Biopharma
- Proposed issue of securities - RGT
- Notification of cessation of securities - RGT
- Appendix 4E and 2026 Annual Report
- Appendix 4G and Corporate Governance Statement
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
Later from Argent Biopharma
- Execution of Loan Facility Agreement
- Application for quotation of securities - RGT
- Strategic Focus on Immune Modulation and Longevity
- Date of AGM and Closing Date for Director Nominations
- Notice of Annual General Meeting/Proxy Form
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma